普瑞盛（北京）医药科技开发有限公司

Company Overview GCP ClinPlus Co., Ltd. (hereinafter referred to as GCP) is a combination of three well established companies: Beijing DMS Pharma Ltd., with CRO as its primary business; YiXie ZhongTai MedTech Consulting Ltd, committed to provide medical device product registration and relevant consultation; SMO unit, mainly engaged in Site Management Organization (SMO). All three companies are so mature and distinctive that they can take advantage of each other’s strengths. GCP provides clinical research solutions which are customized and comprehensive, of international standards and making full use of various network and resources. The services of GCP, with the untiring effort of innovation and extending to new field, cover the evaluation and counseling of new drug R&D, regulatory affairs, clinical trial monitoring and management, data management, statistical analysis, medical affair and training, involving fields of pharmaceutical, biological product and medical device. GCP is of a well trained professional team. All the operation team members have various professional backgrounds of clinical medicine, pharmacy or nursing etc. The management team is composed of group of senior people with deep knowledge of clinical medicine, pharmacy or biometrics and with rich experience of management. All of them have had over 10 years experience in various management positions in multinational pharmaceutical companies as well as famous CRO companies. In early 2011, GCP signed the JV agreement with CMIC Co., Ltd. to enhance the capability and widen the geographic coverage. The win-win cooperation would surely enhance the core competitiveness and open a new chapter of accelerating development of GCP. 公司概况 普瑞盛（北京）医药科技开发有限公司由三家发展成熟，各具特色，优势互补的公司合并组成：以CRO业务为主体的北京迪美斯科技发展有限公司；提供全程医疗器械产品注册及咨询服务的医协众泰；以Site Management Organization (SMO) 业务为主体的博尔泰科。 普瑞盛致力于提供全方位的、符合国际标准的、充分利用人脉和地域资源的个性化临床研究解决方案。在坚持创新和拓展新领域的不懈努力下，普瑞盛的服务涵盖新药研发评估与咨询，注册事务，临床试验实施，数据管理和统计分析，医学事务及培训；业务范围涉及制药、生物技术和医疗器械等。 普瑞盛拥有一支富有拼搏精神的专业队伍，临床运营团队均具有临床医学、药学、护理学等背景；管理团队是由一批具有丰富临床医学、药学、生物统计学及管理学等经验丰富的资深人士组成，且皆拥有逾十年的跨国制药企业及著名CRO从业经历。 2011年初，普瑞盛（北京）医药科技开发有限公司引入外资，与日本希米科株式会社正式签定合资协议，成为中外合资企业。强手联合，增强了核心竞争力，揭开了快速发展的新篇章。